To assess targeting of angiogenesis (via VEGF) and EGFR- and RET-dependent tumor cell growth, anticancer efficacy will be assessed in this clinical trial primarily by the extent of tumor necrosis and percentage of viable tumor in the resected liver tissue, in addition to the measurement of relevant blood biomarkers. This evidence concerns the gene RET and neoplasm.